Iguana Healthcare Management LLC Buys 200,000 Shares of Sierra Oncology Inc (SRRA)

Iguana Healthcare Management LLC lifted its stake in Sierra Oncology Inc (NASDAQ:SRRA) by 33.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 800,000 shares of the biotechnology company’s stock after buying an additional 200,000 shares during the quarter. Sierra Oncology makes up 1.9% of Iguana Healthcare Management LLC’s holdings, making the stock its 16th largest position. Iguana Healthcare Management LLC owned about 1.53% of Sierra Oncology worth $2,984,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Acadian Asset Management LLC raised its holdings in Sierra Oncology by 112.3% in the 4th quarter. Acadian Asset Management LLC now owns 32,437 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 17,161 shares during the period. Candriam Luxembourg S.C.A. acquired a new position in Sierra Oncology in the 4th quarter worth about $2,238,000. Bank of New York Mellon Corp acquired a new position in Sierra Oncology in the 4th quarter worth about $280,000. Sphera Funds Management LTD. acquired a new position in Sierra Oncology in the 4th quarter worth about $2,052,000. Finally, AWH Capital L.P. acquired a new position in Sierra Oncology in the 4th quarter worth about $2,555,000. Hedge funds and other institutional investors own 43.32% of the company’s stock.

How to Become a New Pot Stock Millionaire

Separately, Zacks Investment Research cut Sierra Oncology from a “hold” rating to a “sell” rating in a report on Friday, March 2nd.

Sierra Oncology stock opened at $2.32 on Monday. The firm has a market capitalization of $165.64, a PE ratio of -2.73 and a beta of 2.29. Sierra Oncology Inc has a fifty-two week low of $1.10 and a fifty-two week high of $4.09.

Sierra Oncology (NASDAQ:SRRA) last released its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. During the same period last year, the firm posted ($0.30) earnings per share. research analysts predict that Sierra Oncology Inc will post -0.87 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Iguana Healthcare Management LLC Buys 200,000 Shares of Sierra Oncology Inc (SRRA)” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.com-unik.info/2018/03/19/iguana-healthcare-management-llc-buys-200000-shares-of-sierra-oncology-inc-srra.html.

Sierra Oncology Company Profile

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

Want to see what other hedge funds are holding SRRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sierra Oncology Inc (NASDAQ:SRRA).

Institutional Ownership by Quarter for Sierra Oncology (NASDAQ:SRRA)

Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit